A2B694

Description

A2B694 is an experimental therapy being developed by A2 Biotherapeutics Inc. It is a type of immunotherapy called CAR T-cell therapy. This therapy is being studied in clinical trials for certain types of solid tumors, including colorectal cancer (CRC). Specifically, it is being investigated in patients whose tumors express a protein called mesothelin (MSLN) and have lost a specific marker called HLA-A*02. The therapy involves collecting a patient's own T cells (a type of immune cell), modifying them in a lab to target mesothelin-expressing cancer cells, and then infusing these modified cells back into the patient. A2B694 is currently in Phase 1 clinical trials to determine its safety and find the right dose for patients with advanced solid tumors. It is not yet approved for use in CRC or any other cancer.

Mechanism of Action

A2B694 is a CAR T-cell therapy designed to target cancer cells that express the protein mesothelin (MSLN). The therapy uses a patient's own T cells, which are genetically modified to include a Chimeric Antigen Receptor (CAR). This CAR allows the T cells to recognize and bind to mesothelin on the surface of cancer cells. The CAR also includes a 'safety switch' component designed to prevent the T cells from attacking healthy cells that also express mesothelin but retain the HLA-A*02 marker. The goal is for the modified T cells to specifically attack and kill cancer cells expressing mesothelin while sparing healthy tissue.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials